BREATHE III Brazilian Registry of Heart Failure
Summary
NIH registered BREATHE III, a prospective multicenter observational registry on ClinicalTrials.gov studying acute heart failure patients in Brazil. The 12-month follow-up study will assess patient characteristics, treatment patterns, guideline-directed medical therapy adherence, time to treatment optimization, and clinical outcomes including barriers to implementation and regional variations in care.
What changed
NIH registered a new observational study (BREATHE III) on ClinicalTrials.gov documenting a prospective multicenter registry investigating acute heart failure in Brazil. The study aims to evaluate patient characteristics, guideline-directed medical therapy adherence, time to treatment optimization, and clinical outcomes over 12 months of follow-up.
For healthcare providers and clinical researchers participating in or referring to this registry, the study represents an observational research initiative with no regulatory compliance obligations. The registry may inform future heart failure treatment guidelines and clinical practice patterns in Brazil but does not establish new legal or regulatory requirements.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
III Brazilian Registry of Heart Failure
Observational NCT07534163 Kind: OBSERVATIONAL Apr 16, 2026
Abstract
BREATHE III is a prospective, multicenter, observational registry designed to provide contemporary insights into the epidemiological, clinical, and prognostic characteristics of patients hospitalized with acute heart failure (AHF) in Brazil, including those with decompensated heart failure or new-onset ventricular dysfunction during acute myocardial infarction.
Recent evidence, such as the STRONG-HF trial, has demonstrated the prognostic benefit of rapid initiation and up-titration of guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). However, prior phases of the BREATHE registry did not evaluate the timing of therapeutic optimization or barriers to implementing these strategies. Additionally, the therapeutic landscape of heart failure has evolved substantially in recent years, with the introduction of novel pharmacological agents, expanded indications for existing therapies, and new treatment options for heart failure with preserved ejection fraction (HFpEF).
BREATHE III aims to address these knowledge gaps by systematically assessing, over a 12-month follow-up, patient characteristics, treatment patterns, adherence to guideline-recommended therapies, time to treatment optimization, and clinical outcomes. The study will also identify barriers to the implementation and titration of evidence-based therapies, evaluate regional variations in care, and describe contemporary management practices across public and p...
Conditions: Heart Failure
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.